Introduction
P-selectin glycoprotein ligand-1 (PSGL-1), as one of the very important cellular adhesive molecules, is expressed on the surface of various hematopoietic cells [1] [2] [3] . PSGL-1 is the major ligand for P-selectin, which is expressed at the surface of endothelial cells, especially in the ischemic or damaged endothelium [4] . It has been reported that the interaction between PSGL-1 and P-selectin leads to the activation of Syk, Src family, or other protein kinases in different kinds of cells, and initiates activation of integrin. The activated integrin binds to ICAM-1, which is expressed by stimulated endothelial cells, and leads to firm intercellular adhesion. PSGL-1 has been proved to participate in the recruitment of circulating endothelial progenitor cells (EPCs) to sites of neovascularization [5] ; however, the signaling mechanism downstream of PSGL-1 is unclear in EPCs.
EPCs play a very important role in neovascularization of ischemic tissues and artery endothelium repair through their ability to integrate vascular endothelial cells on new blood vessels and/or to secrete proangiogenic factors [6 -8] . In recent years, many studies have shown that as cell-based therapeutic strategies, EPCs transplantation have many attractive features for improvement of neovascularization and tissue regeneration, but their efficacy was limited by the fact that few of the transplanted cells accumulate in the ischemic and damage tissue [9] . So, it is necessary to develop novel EPCs transplantation strategies that improve revascularization of ischemic tissues.
Adhesion is the first and crucial step for the homing of EPCs to ischemia sites. In the present study, we examined the effect of overexpression of PSGL-1 on EPCs adherence affinity and explored the underlying mechanisms by which PSGL-1 mediates the adhesion activity of EPCs.
Materials and Methods

Materials
Endothelial cell medium was purchased from ScienCell Research Laboratories (San Diego, USA). Rabbit anti-human PSGL-1 polyclonal antibody, mouse anti-rat Syk polyclonal antibody, HRP-conjugated anti-rabbit IgG, goat anti-rabbit IgG-Rhodamine (TRITC) were obtained from Santa Cruz (Santa Cruz, USA), anti-phospho tyrosine antibody was the product of Upstate (Upstate, Lake Placid, USA). FITC-conjugated b2-integrin antibody was purchased from BD Biosciences (San Jose, USA). The Dil-AC-LDL [1,1 0 -dioctadecyl-3,3,3 0 ,3 0 -tetramethylindocarbocyanine perchlorate acetylated low-density lipoprotein (LDL); Invitrogen, Carlsbad, USA] and FITC-Lectin-UEA-1 (Sigma-Aldrich, St. Louis, USA) were used to identify the isolated EPCs. RT-PCR kit was purchased from TaKaRa (Dalian, China), human recombinant P-selectin-Fc fusion proteins and rat recombinant ICAM-1-Fc chimera was purchased from R&D system (Minneapolis, USA).
Isolation, culture, and identification of rat bone marrow-derived EPCs EPCs were isolated and cultured as described previously [10] . Briefly, bone marrow was harvested from both femurs and tibias of 3-4 weeks male Wistar rats (Experimental Animal Center, Chinese Academy of Medical Sciences, Beijing, China). Mononuclear cells were fractionated by density gradient centrifugation (density at 1.083 g/ml). Cells were then cultured on dishes coated with gelatin (1%) in endothelial cell medium supplemented with 5% fetal calf serum, recombinant human VEGF (10 ng/ml), recombinant bovine basic fibroblast growth factor (bFGF, 1 ng/ml), human epidermal growth factor (10 ng/ml), and antibiotics. After 7 days of culture, the EPCSs were identified by its uptake of DiI-labeled acetylated LDL and its binding to Ulex europaeus agglutinin-1 lectin, anti-vascular endothelial cadherin, anti-FactorVIII, and anti-VEGFR2. Adherent cells were able to take up DiL-AC-LDL and to bind FITC-lectin-UEA-1 (Fig. 1) , and were also positive for vascular endothelial cadherin, FactorVIII and VEGFR2 (see Supplementary data).
EPCs transfection with adenovirus
EPCs were transduced with an adenovirus encoding the human PSGL-1 gene (Ad-PSGL-1) or control adenovirus (Ad, containing GFP) as described by Iwaguro et al. [11] . To establish optimal conditions for EPCs adenovirus transfection, serum concentration, virus incubation time, and virus concentration were evaluated. After preliminary experiments were performed, EPCs were transfected with 200 multiple of infection (MOI) of Ad-PSGL-1 or Ad for 24 h in 1% serum media. After transfection, EPCs were washed in PBS and incubated with endothelial cell medium at 378C.
Semiquantitative RT-PCR analysis showed that PSGL-1 mRNA expression was upregulated in EPCs transfected with Ad-PSGL-1, compared with that transfected with control Ad [ Fig. 2(A) ]. Western blot also showed that protein expression level of PSGL-1 was significantly increased in EPCs transfected with Ad-PSGL-1 [ Fig. 2(B) ].
Total RNA extraction and RT-PCR Total RNA was extracted from adenovirus transfected EPCs with Trizol (Invitrogen) and quality of RNA was determined in 1.2% formaldehyde-agarose gel. The cDNA 
Western blot analysis
After different treatment, EPCs were lysed with extraction buffer ( pH 7.5, 20 mM HEPES, 1% NonidetP-40, 10% glycerol, 2.5 mM 4-nitrophenylphosphate, 0.5 mM PMSF, 150 mM NaCl, 10 mM NaF, 1 mM Na 3 VO 4 , and 1 tablet of complete proteinase inhibitor cocktail (Roche, Indianapolis, USA). Cell lysates were centrifuged (12,000Â g, 20 min, 48C), and the supernatants were collected as protein samples. Protein concentrations were determined using Bio-Rad DC protein assay reagents (Bio-Rad, Hercules, USA). The protein homogenates were diluted 1:1 (v/v) with SDS sample buffer containing 40 mM Tris -HCl ( pH 6.8), 4% SDS, 8 mM EGTA, 0.01% bromophenol blue, 4% 2-mercaptoethanol, and 40% glycerol, and then they were boiled for 5 min. Proteins (50 mg per lane) were separated using 12% polyacrylamide SDS gels and then transferred electrophoretically to apolyvinylidene fluoride membrane (Millipore, Bedford, USA). The membrane was then blocked with PBS containing 0.05% Tween-20 and 5% fat-free dried milk for 1 h at room temperature. The membranes were incubated with primary antibodies diluted 1:1000-1:2000 overnight at 48C. Immune complexes were detected with peroxidase-conjugated antibodies (Amersham-Pharmacia, Piscataway, USA) diluted 1:1000 and incubated for 1 h at room temperature. The signal was revealed with an enhanced chemiluminescence system (Pierce Biotechnology, Rockford, USA), used as recommended by the manufacturer and exposed to photographic film. Protein bands intensity was measured by computer analysis using Quantitation software (Bio-Rad).
Monolayer preparation
To prepare the P-selectin fusion protein or the ICAM-1 fusion protein monolayer, the 24-well culture plates were coated with 100 ml of human recombinant P-selectin fusion proteins (40 mg/ml in PBS) or recombinant rat ICAM-1 fusion proteins (40 mg/ml in PBS), respectively for 2 h at room temperature. To prepare the P-selectin/ICAM-1 monolayer, the 24-well culture plates were simultaneously coated with 100 ml of each recombinant P-selectin and ICAM-1. After a gentle PBS wash, the plate was filled with calcium-enriched PBS (DPBS) to activate P-selectin and stored overnight at 48C. Then a total of 5Â10 4 EPCs transfected with Ad-PSGL-1 or control Ad were added to each well. After 1 h of incubation at 378C, cells were washed twice with M199 medium to remove nonadhered cells, fixed in 1% glutaraldehyde, the total number of adhesive EPCs in each well was counted in a blinded manner under 200Â magnification field of a microscope.
EPCs adhesion assay
EPCs adhesion was determined as described by Koga et al. [12] . Briefly, HUVECs were planted using endothelial cell medium into 24-well plates. Confluent human umbilical vein endothelial cell (HUVEC) monolayers were activated with 20 ng/ml TNF-a for 12 h. A total of 5 Â 10 4 EPCs transfected with Ad-PSGL-1 or control Ad were added to each well containing prestimulated HUVEC monolayer. After 1 h of incubation at 378C, cells were washed twice with M199 medium to remove nonadhered cells, fixed in 1% glutaraldehyde. The total number of adhesive EPCs in each well was counted in a blinded manner under 200Â magnification field of a microscope. For inhibition assay, the activated HUVEC monolayers were preincubated with function blocking monoclonal mouse antibodies to human P-selectin, ICAM-1, and VCAM-1 (R&D Systems), respectively, for 1 h, at the optimal concentration according to manufacturer's instructions.
Fluorescence assay
EPCs were incubated on P-selectin monolayer for different time periods, then immediately fixed with 4% paraformaldehyde for 20 min at room temperature and harvested. The expression of b2-integrin on surface of EPCs was detected by staining with FITC-conjugated b2-integrin antibody (10 mg/ml) for 30 min. The levels of surface expression of b2-integrin were analyzed with fluorescence microplate reader (Synergy4, BioTek Instruments, Winooski, USA). Equal number of cells were added to each well, without FITC-labeled b2-integrin antibody staining as blank control, the absorbance (OD values) of all sample wells were normalized by the value of blank.
Immunoprecipitation and detection of phosphorylated Syk
For detection of phosphorylation of Syk, EPCs were incubated on recombinant P-selectin fusion protein monolayer for different time periods, then cells were lysed with the extraction buffer. Lysates containing 500 mg of proteins in extraction buffer were incubated with 4 mg/ml antibody to Syk for 90 min at 48C. The immunocomplex was precipitated using protein A-agarose beads overnight at 48C. Beads were washed with phosphate-buffered saline containing Tween-20 and resuspended in SDS sample buffer and boiled for 5 min. The protein samples collected were immunoblotted with anti-phosphotyrosine antibody to detect phosphorylated Syk. The total Syks were determined by western blotting with anti-Syk antibody and used as loading control. Blots were analyzed by chemiluminescence detection and densitometry. Densitometry quantification results were shown as mean-fold change in phosphorylation.
Statistical analysis
All experiments were repeated more than three times to confirm reproducibility and all data were expressed as the mean + SE. To evaluate the significance of differences between the two groups of experiments, ANOVA and Student's t-test were used, and P , 0.05 was defined as statistically significant.
Results
Overexpression of PSGL-1 enhanced EPCs adhesion to activated HUVEC, and this effect is dependent on P-selectin and ICAM-1 expressed by HUVECs To examine the effect of overexpression of PSGL-1 on EPCs adhesion capability, we used HUVECs stimulated by TNF-a. TNF-a increases the expression of adhesion molecules including P-selectin, ICAM-1, and VCAM-1 in HUVECs. EPCs transfected with Ad-PSGL-1(EPCs-PSGL-1) or control Ad (EPCs-Ad) were combined with TNF-a-stimulated HUVECs. The number of adhering cells of EPCs-PSGL-1 was significantly higher than that of EPCs-Ad (70.31 + 6.20 vs. 39.70 + 3.50, P , 0.01). Statistical analysis showed that EPCs adhesion ability was increased by overexpression of PSGL-1. To exclude the nonspecific binding between two kinds of cells and to examine the specificity of the overexpressed PSGL-1, the block antibody to P-selectin, ICAM-1 and VCAM-1 were added. Results showed that the block antibody to P-selectin and ICAM-1 abolished the increasing effect of PSGL-1 on EPCs adhesion, the block antibody to VCAM-1 had no effect (Fig. 3) .
Overexpression of PSGL-1 enhanced EPCs adhesion to P-selectin/ICAM-1 monolayer
To further confirm the effect of overexpressed PSGL-1 on EPCs adhesion capability, EPCs were combined with the P-selectin, ICAM-1, or P-selectin/ICAM-1 monolayer. Results showed that compared with EPCs-Ad, the adherence of EPCs-PSGL-1 to P-selectin monolayer was 1.5-fold increased (39.82 + 5.38 vs. 26.47 + 4.06, P , 0.05), the adherence of EPCs-PSGL-1 to P-selectin/ ICAM-1 monolayer was 2.0-fold increased (76.78 + 8.42 vs. 37.85 + 6.79, P , 0.01). There was no significant difference between the adherences of EPCs-PSGL-1 and EPCs-Ad to ICAM-1 monolayer. Co-treatment with block antibody to P-selectin or ICAM-1 reversed the increasing effect of overexpressed PSGL-1 on EPCs adherence to P-selectin/ICAM-1 monolayer (Fig. 4, P , 0.01) . These results suggest that the overexpressed PSGL-1 enhances the EPCs adhesion to stimulated HUVECs, and this effect is dependent on both P-selectin and ICAM-1, which are expressed by stimulated HUVECs. After stimulation with P-selectin, the overexpressed PSGL-1 enhanced integrin (receptors for ICAM-1) expression on the surface of EPCs The primary receptors for ICAM-1 are activated by integrins, so we detected whether the overexpression of PSGL-1 enhances integrin activity in EPCs. Integrin activation includes protein distribution and valency change, we investigated whether overexpressed PSGL-1 affects the distribution of integrin on the surface of EPCs. As tested by fluorescence intensity analysis, stimulation with P-selectin caused a 1.7-fold increase of the mean fluorescence intensity for b2-integrin chain 10 min later, a 2.3-fold increase 30 min later on the surface of EPCs-PSGL-1 and only a 1.8-fold increase 30 min later on the surface of EPCs-Ad (Fig. 5) . These results suggest that overexpressed PSGL-1 enhances cell surface expression of b2-integrin, thereby increasing integrin affinity and EPCs adherence to activated HUVECs or P-selectin/ICAM-1 monolayer.
After stimulation with P-selectin, the overexpression of PSGL-1 increased phosphorylation of Syk Syk is one of the important signal-transduction molecules associated with integrin activation in leukocytes, to determine whether the overexpressed PSGL-1 enhances the Syk activation in EPCs, the EPCs extracts were immunoprecipitated with anti-Syk antibody and then immunoblotted with anti-phospho tyrosine antibody. The results showed that overexpression of PSGL-1 elevated Syk phosphorylation in a time-dependent manner, with a maximum at 30 min. In EPCs-PSGL-1, the phosphorylation of Syk was significantly elevated at 5 min, in control EPCs-Ad, the phosphorylation of Syk was significantly increased at 10 min. The phosphorylation of Syk in EPCs-PSGL-1 was significantly higher than that in EPCs-Ad at 5 min. The total expression of Syk, determined using a nonphospho-Syk antibody, did not change during treatment with P-selectin (Fig. 6) . These data suggested that in PSGL-1 overexpressed EPCs, Syk is likely to be more rapidly activated by the interaction between PSGL-1 and P-selectin.
The overexpressed PSGL-1 enhanced integrin activity and EPCs adherence affinity through Syk activation To further determine the role of Syk activation on integrin activation and EPCs adherence affinity, the PSGL-1 overexpressed EPCs were preincubated with a specific Syk inhibitor piceatannol (50 mM, cytotoxicity was abolished, determined by the cytotoxicity test) for 30 min and then incubated with P-selectin fusion protein monolyer for 30 min. Western blotting results showed that the increasing effect of overexpressed PSGL-1 on Syk phosphorylation was significantly inhibited by the treatment of piceatannol. The piceatannol did not influence the total expression of Syk [ Fig. 7(A) ]. In addition the increasing effect of overexpressed PSGL-1 on integrin activation and EPCs adherence affinity was also inhibited by piceatannol (Fig. 7) . These results indicate that overexpressed PSGL-1 increases surface expression of integrin and EPCs adhesive property through Syk-dependent signaling pathway.
Discussion
EPCs are bone marrow-derived cells that circulate in the peripheral blood and have the ability to differentiate into vascular endothelial cells. Studies have shown that the implantation of EPCs improves neovascularization and capillary density of ischemic tissue [7] . Despite their Figure 4 Overexpressed PSGL-1 enhanced EPCs adherence to P-selectin/ICAM-1 monolayer The EPCs transfected with Ad-PSGL-1 (EPCs-PSGL-1) or control Ad (EPCs-Ad) were combined with P-selectin fusion protein, ICAM-1 fusion protein or P-selectin/ICAM-1 fusion protein monolayer, respectively, then adhesive EPCs were calculated. *P , 0.05 vs. EPCs-Ad þ P-selectin. # P , 0.01 vs. EPCs-Ad þ P-selectin/ICAM-1 and EPCs-PSGL-1 þ P-selectin. Figure 5 Overexpressed PSGL-1-enhanced b2-integrin expression on the surface of EPCs EPCs were incubated on P-selectin monolayer for the indicated time periods. The expression of b2-integrin on surface of EPCs was detected by FITC-conjugated b2-integrin antibody staining, then analyzed by fluorescence microplate reader. *P , 0.01 vs. 0 min, # P , 0.01 vs. EPCs-Ad.
obvious potential in clinical practice, at present the efficacy of EPCs transplantation was mainly limited by the fact that few of the injected cells were recruited in the damage tissue. The accumulation of EPCs in ischemic tissues and the incorporation of EPCs into vascular structures require a coordinated sequence of multi-step adhesive and signaling events including initial adhesion, firm adhesion, transmigration, and differentiation into endothelial cells [13] , so the adhesive properties of EPCs is one of the key factors for the improvement of ischemic diseases treatment. There are some cellular adhesion molecules, which have been proved to participate in the regulation of EPCs adhesion to activated endothelial cells in damaged tissues, such as PSGL-1, integrin, and ICAM-1 [6, 14] . PSGL-1 is a ligand for P-selectin, which is expressed in vascular endothelial cells activated in response to the ischemic injury, cytokines, and damaging stimulation. Experimental studies have suggested that interaction of PSGL-1 with P-selectin mediates tethering, rolling, and initial weak adhesion of EPCs to activated endothelial cells, during which EPCs become sufficiently activated in situ by locally released cytokines for integrin activation, then the activated integrin binds with ICAM-1 and mediates firm adhesion [15, 16] . Many observations have implicated that the interaction between PSGL-1 and P-selectin is a critical event in the adhesion and homing of EPCs, and is very important for neovascularization of ischemic tissue; however, the molecular mechanisms downstream of PSGL-1 are unclear in EPCs.
The results of the present study showed that the overexpression of PSGL-1 significantly enhances the EPCs adhesion to TNFa-activated HUVEC monolayer. Since the activated HUVECs express many adhesion molecules including P-selectin, VCAM-1, and ICAM-1, to exclude the nonspecific binding between two kinds of cells and to examine the specificity of the overexpressed PSGL-1, the block antibody to P-selectin, ICAM-1, and VCAM-1 were added. Results showed that the blocking antibody to P-selectin and ICAM-1 abolished the increasing effect of overexpressed PSGL-1 on EPCs adhesion. The monolayer adhesion assay also showed that compared with control EPCs, the adherence of PSGL-1-overexpressed EPCs to P-selectin/ICAM-1 monolayer was increased by 2 fold, and co-treatment with blocking antibody to P-selectin or ICAM-1 reversed the increasing effect. The primary receptor expressed in EPCs for ICAM-1 is integrin. These results suggested that the overexpressed PSGL-1 increases the EPCs adhesion capacity through two mechanisms: first, the overexpressed PSGL-1 binds to P-selectin; then, the PSGL-1 enhances the activation of integrin, which is associated with ICAM-1, and mediates firm adhesion. So the overexpressed PSGL-1 increases the EPCs adhesion activity through the interaction between PSGL-1 and P-selectin and more importantly the subsequent activation of integrin on the EPCs surface.
To confirm this mechanism, we assessed the expression of b2-integrin, one of the major subunits of integrin, on the surface of EPCs. The integrin activity can be regulated at the levels of protein distribution, valency change, and mRNA expression. The short-term stimulation enhances the integrin activity mainly by promoting rapid distribution and valency change [17, 18] .
Results showed that stimulation with P-selectin caused a 1.7-fold increase of the mean fluorescence intensity for b2-integrin chain 10 min later, a 2.3-fold increase 30 min later on the surface of PSGL-1-overepressed EPCs, and only a 1.8-fold increase 30 min later on the surface of control EPCs. These data suggested that overexpressed PSGL-1 enhances the integrin activity on the surface of EPCs, thereby enhancing the EPCs adherence to activated HUVECs and P-selectin/ICAM-1 monolayer. Our results are also in agreement with the previous studies showing that interaction between integrin and ICAM-1 plays a very important role in the homing of EPCs to ischemic tissue.
It has been reported that Syk, Src family kinase, and PKC play an important role in mediating cellular adhesion in different kinds of cells [19] [20] [21] . The signal transduction pathway downstream of PSGL-1 is not fully understood. Syk is highly expressed by EPCs and participates in the reorganization of actin cytoskeleton, which is associated with integrin activation [22, 23] . So to further explore the signaling pathway linking overexpressed PSGL-1 to integrin activation in EPCs, we analyzed the phosphorylation of Syk in EPCs stimulated by P-selectin.
As western blot analysis results showed, the stimulation with P-selectin increased Syk phosphorylation in a timedependent manner, in PSGL-1-overexpressed EPCs the phosphorylation of Syk was significantly elevated after 5 min, in control EPCs the phosphorylation of Syk was significantly increased after 10 min. The Syk phosphorylation level in PSGL-1-overexpressed EPCs was significantly higher than that in the control EPCs 5 min later. These data suggested that in PSGL-1 overexpressed EPCs, the Syk was likely to be more rapidly and highly activated. In addition, the Syk inhibitor piceatannol not only inhibited the Syk phosphorylation but also significantly inhibited the increasing effect of overexpressed PSGL-1 on b2-integrin activation and EPCs adherence affinity.
Taken together, these results suggested that Syk plays an important role in signal transduction downstream of PSGL-1 in EPCs and the overexpression of PSGL-1 improves the EPCs adhesive properties through enhanced activation of Syk and following integrin activation (Fig. 8) .
These results may provide an effective and innovative therapeutic strategy to enhance the recruitment of transplanted EPCs at sites of neovascularization to improve the treatment of ischemic diseases. 
